Creating ‘Zombie’ Cells: Transplanting Genomes into Dead Bacteria for Innovative Research

Microscopic View of Bacterial Colonies: Blue Colonies Represent Synthetic Genomes, While White Colonies Show Survivors of Mitomycin C Treatment.

Credit: Nasaira Assad-Garcia

Researchers have successfully developed living synthetic cells by transplanting complete genomes into deceased bacteria, effectively bringing these microorganisms back to life. This groundbreaking advancement has the potential to revolutionize synthetic biology, allowing for the engineering of living organisms to produce sustainable fuels, pharmaceuticals, and novel materials.

Synthetic biology involves modifying biological systems to introduce new functionalities or create entirely new systems. For instance, scientists can rewrite yeast DNA so that these organisms can synthesize desired chemicals. In 2010, groundbreaking work saw researchers synthesizing bacterial genomes and deploying them into living cells, birthing what they termed as the first synthetic cells.

However, challenges arose; determining whether the cells were genuinely driven by the synthetic genome rather than the original was complex. This issue stemmed from bacteria’s ability to absorb external genetic material via horizontal gene transfer.

To overcome this, John Glass and colleagues at the J. Craig Venter Institute (JCVI) in La Jolla, California, first exterminated the host cell—or at least its genome.

The team employed a chemical called mitomycin C, commonly used in chemotherapy to damage DNA, and tested it on simple bacterial cells of mycoplasma capricolum.

The researchers noted, “The cells remain healthy but are unable to reproduce and their genomes are non-functional, leaving them destined for death or already deceased,” according to Zumra Seidel, also from JCVI.

Next, they introduced a synthetic variant of another bacterial genome from Mycoplasma mycoides into the dead cells through whole-genome transplantation.

Surprisingly, some bacteria began to grow and replicate normally, with genetic tests confirming the presence of synthetic genomes. The team proudly claimed to have engineered the first living synthetic bacterial cells derived from non-living components, dubbing them “zombie cells” due to their revival post-mortem.

“Introducing a genome to a cell devoid of one restores its functionality,” explained Glass.

Kate Adamara from the University of Minnesota commended this research as a pivotal technological breakthrough. “They are embedding genomic information into a non-living recipient with no assistance from the host’s repair systems. Essentially, they have revived that cell,” she noted. “An impressive feat!”

Furthermore, it raises questions about the definitions of life and non-life; traditionally defined by metabolism and replication, these traits are barely present in the recipient cells. “What truly constitutes life?” queried Adamara.

Team member Elizabeth Strychalski from the National Institute of Standards and Technology in Gaithersburg, Maryland, expressed hope that this discovery would encourage viewing biology as fluid processes. “By adopting an engineering perspective, we can analyze living systems and identify which processes are essential for our desired outcomes,” she stated.

This technique has thus far only been tested on mycoplasma, yet the researchers believe it serves as a proof of principle and could significantly expedite the creation of synthetic organisms that function as mini-chemical factories to produce drugs or clean up environmental pollutants.

“While we have long had the capability to assemble remarkable lengths of synthetic DNA, we lacked means to make them operational,” Strychalski remarked. “It’s akin to having a script for a Shakespearean play without the ability to perform it.”

Akos Nierges from Harvard Medical School emphasized that this research tackles a vital hurdle in synthetic biology. “This technology may lead to more predictable and reliable methods for genome transfer across various species,” he said.

Transitioning to more complex organisms like yeast and Escherichia coli could pose challenges due to their cell walls. Still, Glass remains optimistic that this technology can succeed with those genomes too.

“If effective in one organism, it’s likely to succeed in others,” he stated, with ongoing investigations into methods to remove and replace cell walls. “Provided appropriate growth conditions, Escherichia coli can regenerate new cell walls,” he added.

Concerns about biological safety in synthetic biology persist. Although the mycoplasma species examined in this study can be pathogens for goats and cattle, Nierges assured there are no anticipated increases in virulence from these modifications.

Strychalski mentioned that existing best practices in laboratories can significantly reduce the risk of pathogen leakage.

Topics:

  • Biotechnology /
  • Microbiology

Source: www.newscientist.com

Transplanting Pig Livers into Living Humans Achieves Near-Normal Functionality

Surgeons carry out a pig liver transplant at the First Affiliated Hospital of Anhui Medical University in China in May 2024.

Lu Xianfu

Transplants of organs from non-human animals to human recipients could transform medicine and potentially save countless lives each year as many die awaiting transplants. Past experiments have seen pig hearts and kidneys transplanted into humans, but this marks the first instance of an animal liver being transplanted into a living person.

“This is truly groundbreaking,” remarks Heiner Wedemeyer from Hannover Medical School in Germany, who was not involved in the procedure. “The patient was critically ill, but thanks to the transplant, he survived for six months.”

The complexities of the liver have prevented previous surgeries of this kind. Earlier studies were conducted on brain-dead individuals, but indications of success were observed. “The heart acts merely as a muscle for pumping blood,” Wedemeyer explains. “Kidneys are simpler as they filter waste. The liver, however, is unique as it synthesizes a variety of proteins essential for numerous metabolic functions.”

Similar early successes were noted in heart and kidney transplants, although subsequent complications arose. In the realm of heart transplantation, risks potentially include the spread of swine viruses.

Recently, Hokujo Taiyo and colleagues at Anhui Medical University reported a pig liver transplant performed on a 71-year-old man. His liver was deemed too damaged for a traditional transplant due to severe tumor growth and significant scarring from hepatitis B. Thousands perish annually awaiting liver transplants, so each surgical case must be meticulously justified, according to Sun.

However, Sun indicated that the man required some form of transplant as there was a risk of the tumor rupturing, which could be life-threatening. With the patient’s consent, Sun and his team replaced the affected portion of the liver with one harvested from an 11-month-old minipig in May 2024. During a five-hour procedure, they connected the blood vessels of the pig liver to those of the left side of the recipient’s own liver.

To mitigate the risk of rejection by the immune system, three pig genes were disabled while seven human genes were introduced, enhancing compatibility. The patient was also administered immunosuppressants while the team diligently examined his liver to ensure it was free from swine viruses.

Almost immediately post-surgery, the new liver began to produce bile. Bile is crucial for the digestion of fats. Within weeks, levels of bile and albumin (a protein that retains fluid within blood vessels) in the patient rose to healthy ranges, as reported by Sun.

Nevertheless, about a month post-transplant, a life-threatening blood clot formed in a blood vessel, necessitating the removal of the graft. This complication likely stemmed from an overactive immune response, leading to abnormal blood-clotting protein levels—a challenge that may be common in pig transplants given the biological differences between species.

The patient lived for roughly five additional months with only the left side of his liver remaining before succumbing to gastrointestinal bleeding, a frequent issue associated with liver scarring, according to Sun. Both Sun and Wedemeyer believe this bleeding was probably not related to the transplant.

Despite the outcome, the operation is seen as a partial success because the patient would likely have died very soon after the tumor’s removal, noted Wedemeyer. Furthermore, he added that the patient’s liver may have partially regenerated during the successful functioning of the transplant, enabling survival for several months after the graft removal.

Wedemeyer emphasized that this procedure enhanced the understanding of xenotransplantation and opened up the possibility of pig livers providing temporary solutions for patients awaiting human transplants. There may even be a chance that the remaining liver tissue could grow sufficiently to negate the need for further treatment, indicated Sun.

However, Sun cautioned that it may take at least ten years before pig livers can replace human livers permanently. He stressed the need to minimize potential complications through further genetic advancements.

topic:

Source: www.newscientist.com